Sareum Holdings plc is pleased to announce the appointment of Mr. Ernesto Giorgio Reggiani to the Sareum Board with effect from 21 September 2007. As announced on 18 June 2007, Mr. Reggiani was appointed as Finance Director in June this year when it was anticipated that he would be invited to join the board within three months. Mr. Reggiani is a Chartered Management Accountant with 17 years of senior financial experience in companies including Esprit Capital Partners LLP, Vidus Limited and Mobile Systems International plc.

The directors of Sareum believe that Mr. Reggiani brings a wide range of experience to the board and consider him a valuable addition to the team.

Commenting on this announcement, Sareum’s Chairman, Dr Paul Harper, said:I am delighted to announce that Giorgio has joined Sareum’s Board. His strong record of experience will be of great value to Sareum as we continue to advance all elements of our business.”

Mr. Reggiani is, or has been in the previous five years, a director or partner of the following organisations:


Current directorships

Previous directorships

Doppio LLP

Esprit Capital Partners LLP


Prelude Ventures Limited


Interland Concepts Limited


Confignium Limited


The Company confirms there is no other information that falls to be disclosed under Schedule 2 paragraph (g) of the AIM Rules.

For further information: 

Sareum Holdings plc

01223 497700

Tim Mitchell, Chief Executive Officer




Buchanan Communications

020 7466 5000

Tim Anderson, Mary-Jane Johnson




Grant Thornton Corporate Finance

020 7383 5100

Philip Secrett, Colin Aaronson



Notes for editors:

About Sareum Holdings plc

Sareum Holdings plc is a structure-based drug discovery business headquartered in Cambridge, UK. The Company was formed in August 2003 to discover new drugs for the treatment of cancer.  Sareum’s unique approach aims to halve the time it takes to discover new drug candidates.

A structure-based approach to drug discovery relies on knowledge of the three-dimensional structure of the proteins that cause disease.  Once the structure is known, potential drugs are designed to ‘lock-in’ to the protein with the aim of reversing or arresting a disease’s progression.  Knowledge of the structure of the potential drugs and how they ‘lock-in’ to their target protein assists greatly in the development of high-quality drug candidates.  Determining structure is a complex task and requires leading-edge equipment and experienced staff.  Sareum’s approach to structure determination utilises its proprietary protein expression platform in order to produce multiple recombinant proteins that accelerate structure determination using x-ray crystallography.

Once the structure is determined, the Company’s innovative fragment screening platform is used to identify novel chemical templates designed to interact with the target protein.  Sareum then uses its high-throughput medicinal chemistry platform to rapidly optimise these molecules and develop the most promising into potential drug candidates.

Sareum aims to successfully deliver drug candidates for licensing to larger pharmaceutical companies at the pre-clinical or early clinical trials stage.  This is funded by provision of its specialist drug discovery capabilities to partners in the pharmaceutical and biotechnology industries.

Sareum joined the AIM market of the London Stock Exchange in October 2004 and trades under the symbol SAR.  For further information, please visit